Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI ≥27.0 kg/m2

This research study is investigating a new medicine called petrelintide, which is being developed to help with weight reduction. The main goal is to find out exactly how this medicine behaves in the body. This involves understanding how much medicine gets into the bloodstream, how long it stays there, and how the body processes and removes it. To do this, researchers will give petrelintide at different strengths to adult participants who have a body mass index (BMI) of 27 or higher, which means they are considered overweight or obese. This is an early-stage study, meaning it's one of the first times this medicine is being tested in humans.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Zealand Pharma A/S

Enrolment target

Start

17 Nov 2025

Weight reduction

What is this study about?

This study is about a new medicine called petrelintide, which could potentially help people with weight reduction. When new medicines are developed, scientists need to understand how they work in the human body. This is called 'pharmacokinetics', which might sound complicated, but it simply means learning how the body takes in the medicine, how it travels around, how it's changed by the body, and finally, how it leaves the body.

In this particular study, researchers will be looking at how petrelintide behaves in the body when given at different strengths or "concentrations." They want to see if changing the strength affects how much medicine gets into the bloodstream, how long it stays there, and how quickly the body gets rid of it. This information is really important because it helps scientists work out the best and safest dose to use in the future.

This is an early-stage study, often called a Phase 1 study. This means it's one of the first times human volunteers are receiving the medicine. These studies are crucial for gathering basic safety information and understanding how the medicine acts in the body before it can be tested in larger groups of people.

Key takeaways

Study for a new weight-reduction medicine called petrelintide.
Aimed at understanding how the body handles the medicine.
Open to adults aged 18 and older, both men and women.
Participants must have a BMI of 27 or higher (overweight or obese).
It's an early-stage study (Phase 1) focused on safety and how the medicine works.
Participation helps scientists find the best future dose for this medicine.

Who may be eligible?

To join this study, participants need to be adults, aged 18 years or older, with no upper age limit. Both men and women are welcome to take part.

Participants must have a Body Mass Index (BMI) of 27 or higher. Your BMI is a measure that uses your height and weight to work out if your weight is healthy. A BMI of 27 or above generally means you are considered overweight or obese.

Before taking part, a healthcare professional will carefully check your overall health and medical history to make sure the study is safe and suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Are you male or female?
Do you have a Body Mass Index (BMI) of 27 or higher?
Are you generally in good health (as determined by a doctor)?
Are you able to attend study visits regularly?

Answer every question to see your result.

What does participation involve?

The detailed plan for taking part isn't fully described, but typically in this type of early study, you would visit a clinic regularly. This would involve receiving the study medicine, likely petrelintide, and having regular checks. These checks usually include blood tests to measure the medicine in your body, as well as physical exams and possibly other tests to monitor your health and safety. The total duration of participation and the number of visits would be explained in full detail by the study team.

Potential risks and benefits

Potential benefits of taking part might include contributing to scientific knowledge about a new weight reduction medicine, which could help future patients. You would also receive close medical attention during the study. As with all medicines, there are potential risks, including side effects from petrelintide. These would be fully explained by the study team. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Germany

Common questions

What is petrelintide?

Petrelintide is a new medicine being studied for its potential to help with weight reduction.

What does 'pharmacokinetics' mean?

It's a scientific term for how your body handles a medicine – how it absorbs, distributes, breaks down, and gets rid of it.

Why is BMI important for this study?

Participants need to have a BMI of 27 or higher because the study is focused on people who are overweight or obese.

Is this medicine available to the public yet?

No, this is an early-stage research study, so petrelintide is not yet approved and available for public use.

Will I lose weight on this study?

While the medicine is for weight reduction, the main goal of this particular study is to understand how the body processes the medicine, not specifically to achieve weight loss in participants.